COVID-19 vaccine safety monitoring in Republic of Korea from February 26, 2021 to October 31, 2021
Objectives This study aimed to present data on reported adverse events following coronavirus disease 2019 (COVID-19) vaccination in Republic of Korea from February 26 to October 31, 2021, and to determine whether any significant patterns emerged from an analysis of the characteristics of suspected a...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Korea Disease Control and Prevention Agency
2021-12-01
|
| Series: | Osong Public Health and Research Perspectives |
| Subjects: | |
| Online Access: | http://ophrp.org/upload/pdf/j-phrp-2021-0310.pdf |
| _version_ | 1797719425644756992 |
|---|---|
| author | Insob Hwang Kyeongeun Park Tae Eun Kim Yunhyung Kwon Yeon-Kyeng Lee |
| author_facet | Insob Hwang Kyeongeun Park Tae Eun Kim Yunhyung Kwon Yeon-Kyeng Lee |
| author_sort | Insob Hwang |
| collection | DOAJ |
| description | Objectives This study aimed to present data on reported adverse events following coronavirus disease 2019 (COVID-19) vaccination in Republic of Korea from February 26 to October 31, 2021, and to determine whether any significant patterns emerged from an analysis of the characteristics of suspected adverse event cases for each type of vaccine. Methods Adverse events following COVID-19 vaccination reported by medical doctors and forensic pathologists were analyzed. Cases of suspected anaphylaxis were classified using the Brighton Collaboration definition. Results By October 31, 2021, a total of 353,535 (0.45%) adverse events were reported after 78,416,802 COVID-19 vaccine doses. Of the adverse events, 96.4% were non-serious and 3.6% were serious. The most frequently reported adverse events were headache, myalgia, and dizziness. Of the 835 reported deaths after COVID-19 vaccination, 2 vaccine-related deaths were confirmed. Suspected anaphylaxis was confirmed in 454 cases using the Brighton Collaboration definition. Conclusion The commonly reported symptoms were similar to those described in clinical trials. Most reported adverse events were non-serious, and the reporting rate of adverse events following COVID-19 vaccination was higher in women than in men (581 vs. 315 per 100,000 vaccinations). Confirmed anaphylaxis was reported in 5.8 cases per 1,000,000 vaccinations. |
| first_indexed | 2024-03-12T09:05:47Z |
| format | Article |
| id | doaj.art-6968b2d74ee34853b3132a12b0d8c19a |
| institution | Directory Open Access Journal |
| issn | 2210-9099 2210-9110 |
| language | English |
| last_indexed | 2024-03-12T09:05:47Z |
| publishDate | 2021-12-01 |
| publisher | Korea Disease Control and Prevention Agency |
| record_format | Article |
| series | Osong Public Health and Research Perspectives |
| spelling | doaj.art-6968b2d74ee34853b3132a12b0d8c19a2023-09-02T15:20:43ZengKorea Disease Control and Prevention AgencyOsong Public Health and Research Perspectives2210-90992210-91102021-12-0112639640210.24171/j.phrp.2021.0310642COVID-19 vaccine safety monitoring in Republic of Korea from February 26, 2021 to October 31, 2021Insob Hwang0Kyeongeun Park1Tae Eun Kim2Yunhyung Kwon3Yeon-Kyeng Lee Adverse Event Management Team, Post-vaccination Management Group, COVID-19 Vaccination Task Force, Korea Disease Control and Prevention Agency, Cheongju, Korea Adverse Event Management Team, Post-vaccination Management Group, COVID-19 Vaccination Task Force, Korea Disease Control and Prevention Agency, Cheongju, Korea Adverse Event Management Team, Post-vaccination Management Group, COVID-19 Vaccination Task Force, Korea Disease Control and Prevention Agency, Cheongju, Korea Adverse Event Management Team, Post-vaccination Management Group, COVID-19 Vaccination Task Force, Korea Disease Control and Prevention Agency, Cheongju, KoreaObjectives This study aimed to present data on reported adverse events following coronavirus disease 2019 (COVID-19) vaccination in Republic of Korea from February 26 to October 31, 2021, and to determine whether any significant patterns emerged from an analysis of the characteristics of suspected adverse event cases for each type of vaccine. Methods Adverse events following COVID-19 vaccination reported by medical doctors and forensic pathologists were analyzed. Cases of suspected anaphylaxis were classified using the Brighton Collaboration definition. Results By October 31, 2021, a total of 353,535 (0.45%) adverse events were reported after 78,416,802 COVID-19 vaccine doses. Of the adverse events, 96.4% were non-serious and 3.6% were serious. The most frequently reported adverse events were headache, myalgia, and dizziness. Of the 835 reported deaths after COVID-19 vaccination, 2 vaccine-related deaths were confirmed. Suspected anaphylaxis was confirmed in 454 cases using the Brighton Collaboration definition. Conclusion The commonly reported symptoms were similar to those described in clinical trials. Most reported adverse events were non-serious, and the reporting rate of adverse events following COVID-19 vaccination was higher in women than in men (581 vs. 315 per 100,000 vaccinations). Confirmed anaphylaxis was reported in 5.8 cases per 1,000,000 vaccinations.http://ophrp.org/upload/pdf/j-phrp-2021-0310.pdfcovid-19safetyvaccines |
| spellingShingle | Insob Hwang Kyeongeun Park Tae Eun Kim Yunhyung Kwon Yeon-Kyeng Lee COVID-19 vaccine safety monitoring in Republic of Korea from February 26, 2021 to October 31, 2021 Osong Public Health and Research Perspectives covid-19 safety vaccines |
| title | COVID-19 vaccine safety monitoring in Republic of Korea from February 26, 2021 to October 31, 2021 |
| title_full | COVID-19 vaccine safety monitoring in Republic of Korea from February 26, 2021 to October 31, 2021 |
| title_fullStr | COVID-19 vaccine safety monitoring in Republic of Korea from February 26, 2021 to October 31, 2021 |
| title_full_unstemmed | COVID-19 vaccine safety monitoring in Republic of Korea from February 26, 2021 to October 31, 2021 |
| title_short | COVID-19 vaccine safety monitoring in Republic of Korea from February 26, 2021 to October 31, 2021 |
| title_sort | covid 19 vaccine safety monitoring in republic of korea from february 26 2021 to october 31 2021 |
| topic | covid-19 safety vaccines |
| url | http://ophrp.org/upload/pdf/j-phrp-2021-0310.pdf |
| work_keys_str_mv | AT insobhwang covid19vaccinesafetymonitoringinrepublicofkoreafromfebruary262021tooctober312021 AT kyeongeunpark covid19vaccinesafetymonitoringinrepublicofkoreafromfebruary262021tooctober312021 AT taeeunkim covid19vaccinesafetymonitoringinrepublicofkoreafromfebruary262021tooctober312021 AT yunhyungkwon covid19vaccinesafetymonitoringinrepublicofkoreafromfebruary262021tooctober312021 AT yeonkyenglee covid19vaccinesafetymonitoringinrepublicofkoreafromfebruary262021tooctober312021 |